28 April 2015: London, UK, and Cambridge, USA – Alacrita, the transatlantic life science consulting firm, today announced the appointment of Dr. Christine McCarthy MD as Associate Partner. Dr. McCarthy joins Alacrita from Sanofi, where she was most recently responsible for the scientific evaluation and due diligence of external business development opportunities, with a focus on metabolic diseases.
Before joining the scientific assessment team at Sanofi, Dr McCarthy led the late stage clinical development of one of the company’s drugs in diabetes, obesity and cardiovascular indications, securing approval of the drug in the European Union. She then worked alongside Sanofi’s Business Development group, providing technical and medical due diligence support across multiple therapeutic areas, principally metabolic diseases, urology and rheumatology. She has broad technological experience and has worked on small molecules, peptides, monoclonal antibodies, new formulations, long acting peptides and drug device combinations.
Christine joins Alacrita’s team of expert drug development consultants, all of whom have established track records of developing novel pharmaceuticals. This expertise is regularly deployed to help biotech and pharma companies with clinical strategy, and to support investment and licensing decisions by big pharma and investors.
Christine McCarthy said “I am delighted to be joining the Alacrita team, which has an impressive track record of providing due diligence and scientific assessment to pharma companies and investors in the life sciences. The development of novel drugs to treat metabolic diseases is particularly challenging, and I look forward to working alongside Alacrita to share my insights and expertise with the biotech and pharma communities.”
Rob Johnson, Partner at Alacrita, said: “We are delighted to welcome Dr. McCarthy to the Alacrita team as we continue to build a best-in-class pharma consulting practice. Christine has rare expertise in the development of new agents to treat diabetes and other metabolic conditions and has an impressive insight into the pipeline of emerging therapeutics in this field. She joins a high caliber team of seasoned consultants and underlines our commitment to providing exceptionally high quality advice to the industry.”